Evidence from the STAR Study: A Novel Low-dose Atropine Eye Drop Slows the Progression of Pediatric Myopia

The Phase 3 STAR trial represents a significant step forward in understanding how low-dose atropine may help preserve vision in children with progressive myopia. By studying a broad population of patients across multiple geographies, the results provide meaningful evidence of SYD-101’s potential to address one of the most urgent unmet needs in pediatric ophthalmology.